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Chitosan oligosaccharides were modified with N-diazeniumdiolates to yield biocompatible nitric oxide (NO) donor scaffolds.
The minimum bactericidal concentrations and MICs of the NO donors against Pseudomonas aeruginosa were compared under
aerobic and anaerobic conditions. Differential antibacterial activities were primarily the result of NO scavenging by oxygen un-
der aerobic environments and not changes in bacterial physiology. Bacterial killing was also tested against nonmucoid and mu-
coid biofilms and compared to that of tobramycin. Smaller NO payloads were required to eradicate P. aeruginosa biofilms under
anaerobic versus aerobic conditions. Under oxygen-free environments, the NO treatment was 10-fold more effective at killing
biofilms than tobramycin. These results demonstrate the potential utility of NO-releasing chitosan oligosaccharides under both
aerobic and anaerobic environments.
Pseudomonas aeruginosa is an opportunistic human pathogenthat frequently colonizes people with compromised immune
systems, such as those with cystic fibrosis (CF) or severe burn
wounds (1). The success of P. aeruginosa as a pathogen is related to
its multitude of virulence factors, which increase adherence to the
host cells, induce inflammation, and disrupt the host immune
response (1). Furthermore, P. aeruginosa is intrinsically resistant
to many antibiotics due to low membrane permeability and in-
creased expression of -lactamases and efflux pumps (2–4). In
addition to this native resistance, P. aeruginosa readily adapts to
antibiotic challenge by acquiring resistance genes (3, 5) and form-
ing protective, cooperative communities known as biofilms (6, 7).
While all antibiotic resistance mechanisms are not fully under-
stood, at least three main factors reduce antibiotic efficacy against
bacterial biofilms compared to planktonic cells. First, P. aerugi-
nosa in biofilms secretes a protective layer of exopolysaccharides
that prevent the diffusion of antibiotics (7). In the context of cystic
fibrosis, biofilm-bound P. aeruginosa exists predominantly as the
mucoid phenotype, characterized by a secreted alginate matrix
that provides a physical barrier against the host immune response
and antibiotics (8). This exopolysaccharide matrix also prevents
the diffusion of oxygen into biofilms, causing P. aeruginosa to
switch from aerobic to anaerobic respiration (9). The reduced
metabolic activity of P. aeruginosa undergoing anaerobic respira-
tion protects the bacterium against traditional antibiotics that are
most effective against rapidly dividing cells, including aminogly-
cosides and -lactams (10, 11). Finally, biofilms produce persister
cells (i.e., dormant bacteria that are highly resistant to chemical
disinfectants and exhibit multidrug tolerance) much more fre-
quently than planktonic bacterial cultures (3, 7).
The failure of conventional antibiotics to treat P. aeruginosa
biofilms and infections necessitates the development of new anti-
bacterial agents. Nitric oxide (NO), an endogenously produced
free radical that can disperse (12, 13) and eradicate (14, 15) bio-
films, holds particular promise as an alternative to current antibi-
otic treatments. Gaseous NO has been repeatedly used to eradicate
P. aeruginosa infections in small-animal models with no apparent
toxicity (16, 17). Under aerobic environments, NO reacts with
molecular oxygen, superoxide, and hydrogen peroxide to form
highly reactive intermediates (peroxynitrite, nitrogen dioxide,
and dinitrogen trioxide). These molecules exert nitrosative and
oxidative stresses, such as DNA deamination, nitrosation of mem-
brane and intracellular proteins, and membrane damage via lipid
peroxidation, culminating in bacterial death (18–21). Some of
these congener molecules, especially peroxynitrite, are more po-
tent antimicrobials than NO alone (19). In anaerobic environ-
ments, NO toxicity is less understood. Ren et al. reported that the
bacteriostatic mechanisms included modification of iron-sulfur
proteins (22). As these proteins are linked to nearly every cellular
process, including metabolism, respiration, RNA modification,
and DNA repair and replication, their alteration greatly influences
bacterial viability (23). The killing activities of NO are expected to
be different under aerobic and anaerobic conditions due to the
differences in bactericidal mechanisms, but this hypothesis has yet
to be studied systematically. As P. aeruginosa grows rapidly and
forms biofilms under both aerobic and anaerobic conditions, un-
derstanding the effects of oxygen on the antibacterial activity of
NO is essential for developing NO-based therapeutics.
While the administration of exogenous NO holds promise as a
therapeutic, treatment of infections or chronic wounds with gas-
eous NO is impractical, expensive, and potentially dangerous, as
NO mediates other physiological processes (e.g., vasodilation and
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blood clotting) (21, 24–26). Macromolecular scaffolds capable of
effectively storing and releasing NO have been developed to en-
able local delivery (27, 28). The most promising NO release vehi-
cles to date include NO donor-modified N-diazeniumdiolate sil-
ica nanoparticles (29–31), dendrimers (32–36), and chitosan (15).
While silica nanoparticles (14, 37–39) and dendrimers (32–34) are
effective as antimicrobials, they do not easily break down and thus
have limited potential as inhaled therapeutics. Chitosan-based
oligosaccharides represent attractive scaffolds for NO delivery, as
they are biodegradable and have low toxicity to mammalian cells
(40, 41). We have previously reported that NO-releasing chitosan
oligosaccharides are capable of NO storage/release and of eradi-
cating P. aeruginosa biofilms under aerobic environments at con-
centrations nontoxic to mammalian cells (15). Here, we evaluate
the antibacterial efficacy of NO-releasing chitosan oligosaccha-
rides as a function of oxygen availability using nonmucoid, mu-
coid, and biofilm P. aeruginosa phenotypes.
MATERIALS AND METHODS
Materials. Medium-molecular-weight chitosan, 2-methylaziridine, and
tobramycin were purchased from Sigma-Aldrich (St. Louis, MO). Meth-
yltrimethoxysilane (MTMOS) was purchased from Fluka (Buchs, Swit-
zerland). (Heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane
(17 FTMS) was purchased from Gelest (Morrisville, PA). Nitric oxide gas
was purchased from Praxair (Sanford, NC). Standardized NO (26.85
ppm; balance N2), argon (Ar), and nitrogen (N2) gases were purchased
from Airgas National Welders (Durham, NC). Sodium methoxide was
purchased from Acros Organics (Geel, Belgium). Distilled water was pu-
rified using a Millipore Milli-Q UV Gradient A-10 system (Bedford, MA).
All common laboratory salts and reagents were purchased from Fisher
Scientific (Pittsburgh, PA). All materials were used without further puri-
fication unless otherwise specified.
Bacterial strains and media. The laboratory P. aeruginosa strain used
in this study was strain K (PAK). The mucoid phenotype was the mucA22
isogenic mutant of the nonmucoid PAK strain. Both bacterial strains were
a gift from Matthew Wolfgang, Department of Microbiology and Immu-
nology, University of North Carolina (UNC) (Chapel Hill, NC). Clinical
isolates were collected from patients at the UNC Hospital Clinical Micro-
biology Laboratory (Chapel Hill, NC). The clinical isolates were screened
for tobramycin resistance using the Kirby-Bauer disk diffusion method
according to standards published by the Clinical and Laboratory Stan-
dards Institute in document M100-S23 (42). All bacteria were grown in
Luria Bertani (LB) broth (BD Biosciences, San Jose, CA) with the pH
adjusted to 6.5 using 10 mM sodium phosphate. When indicated, potas-
sium nitrate (15 mM) was added to the broth. Phosphate-buffered saline
(PBS) was adjusted to pH 6.5 with 10 mM sodium phosphate. All bacterial
media were adjusted to pH 6.5 to more accurately mimic the pH of CF
mucus (22). Anaerobic media were kept in a Coy anaerobic chamber (Coy
Laboratory Products, Ann Arbor, MI) with the lid loosened for 1 week
prior to use.
Synthesis of COS. 2-Methylaziridine-modified chitosan oligosaccha-
rides (COS) (specifically chitosan2-5k) were synthesized as previously
described (15). Briefly, medium-molecular-weight chitosan (2.5 g) was
oxidatively degraded to 5 kDa in 15% hydrogen peroxide for 1 h at 85°C.
The nondegraded chitosan was removed by filtration. The remaining
chitosan oligosaccharides were precipitated from solution with ace-
tone, collected via centrifugation, and dried in vacuo. The 5-kDa
chitosan oligosaccharides (500 mg) were then dissolved in water (10
ml). Concentrated hydrochloric acid (27.6 l), water (250 l), and
2-methylaziridine (356 l) were then added to this solution. The re-
action mixture was stirred for 5 days at 25°C, followed by 24 h at 75°C.
The modified chitosan oligosaccharides were again precipitated with
acetone, collected via centrifugation, and dried in vacuo. The 1H nu-
clear magnetic resonance (NMR) data for COS were (400 MHz, D2O,
): 0.8 –1.1 [NH2CH(CH3)CH2NH], 1.9 (C-7: CHNHCOCH3), 2.3–
2.9 [NH2CH(CH3)CH2NHCH, C-2: NH2CH(CH3)CH2NHCH], 3.3–
4.0 [C-3, C-4, C-5, C-6: OHCH, OCHCH(OH)CH(NH2)CH,
OHCH2CH, OHCH2CH], and 4.4 [C-1: OCH(CHNH2)O].
Synthesis of COS-NO. In order to impart NO storage and release,
N-diazeniumdiolates were formed on the secondary amines of COS (15).
Briefly, COS (15 mg) was dissolved in a solution of water (300 l), meth-
anol (700 l), and 5.4 M sodium methoxide (25 l) in a 1-dram vial
equipped with a stir bar. The open vial was placed in a 160-ml Parr general
purpose stainless steel pressure vessel and rigorously stirred. Oxygen was
removed from the reaction vessel by purging with argon (10 s; 8  105 Pa)
3 times, followed by 3 additional long argon purges (10 min; 8  105 Pa).
The vessel was then filled with potassium hydroxide-purified NO gas
(10  105 Pa) for 72 h at room temperature. Afterward, the argon-purging
procedure was repeated to remove unreacted NO. The N-diazenium-
dolate-modified chitosan oligosaccharides (COS-NO) were precipitated
in acetone, collected via centrifugation, dried in vacuo, and stored at
20°C as a yellow powder.
Chemiluminescence detection of NO release. A Sievers (Boulder,
CO) 280i chemiluminescence nitric oxide analyzer was used for chemilu-
minescence detection of NO from COS-NO (1.0 mg) in 30 ml of deoxy-
genated PBS (pH 6.5) at 37°C. The released NO was carried by N2 gas to
the reaction vessel/detector at a flow rate of 80 ml/min. Additional N2 flow
was supplied to the sample flask at 200 ml/min to match the collection rate
of the instrument. The analysis was terminated when NO concentrations
fell below 10 ppb NO/mg COS-NO. Prior to analysis, the instrument was
calibrated with air passed through an NO zero filter (0 ppm NO) and 26.8
ppm of NO standard gas (balance N2).
Electrochemical detection of NO release. NO-selective electrochem-
ical sensors were fabricated in house as previously reported (43). Briefly,
polished polycrystalline Pt disk electrodes (2 mm) sealed in Kel-F (CH
Instruments, Austin, TX) were coated with an NO-selective membrane
prepared by mixing MTMOS (60 l), ethanol (300 l), 17 FTMS (15 l),
water (80 l), and 0.5 M hydrochloric acid (5 l) for 1 h at 25°C. The
resulting solution was spreadcast over the Pt electrode and dried over-
night at room temperature. Amperometric NO measurements followed,
using a three-electrode setup with the NO-selective membrane-modified
Pt electrode as the working electrode, a Pt-coiled counter electrode, and
an Ag/AgCl reference electrode. The applied potential for NO oxidation
was 700 mV versus Ag/AgCl. Immediately prior to use, the NO sensors
were calibrated by adding a known amount of PBS saturated with NO gas
(1.9 mM) to deoxygenated PBS (pH 6.5). Saturated NO solutions were
made on the day of use by degassing PBS (pH 6.5) for 30 min with Ar,
followed by 20-min purging with NO gas. The sensors were immersed in
10.0 ml of PBS or LB broth (stirred; 37°C) and polarized at 700 mV
versus Ag/AgCl until a stable baseline was achieved prior to the addition of
COS-NO. The NO oxidation current was measured every 0.1 s and ceased
when the current returned to its background value. Measurement of NO
release in anaerobic media was carried out in a Coy anaerobic chamber.
Total NO for 1.0-mg COS-NO/ml solutions are reported as the average
and standard deviation for 4 or more separate measurements.
Planktonic bactericidal assays. Bacteria were grown as overnight cul-
tures, diluted 1:100 in fresh LB broth (with or without nitrate supplemen-
tation), and grown to mid-log phase (2  108 CFU/ml). These cultures
were centrifuged, resuspended in PBS, and diluted to 2  106 CFU/ml in
PBS. Each suspension was then added to vials containing 2-fold serial
dilutions of COS-NO or COS controls and incubated at 37°C for 4 h with
gentle shaking. Following treatment, the bacterial solutions were serially
diluted, spiral plated on LB agar, and incubated for 24 h at 37°C. Colonies
were enumerated using a Flash and Go colony counter (IUL, Farmingdale,
NY). The minimum bactericidal concentration after a 4-h exposure
(MBC
4 h
) was defined as the minimum concentration required to achieve
a 3-log-unit reduction in viable bacteria (from 106 to 103 CFU/ml). The
plating-counting method employed has a limit of detection of 2.5  103
CFU/ml (44). The corresponding NO dose was calculated by multiplying
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the MBC4 h of COS-NO (in milligrams per milliliter) with the available
NO in aerobic and anaerobic PBS (in micromoles NO per milligram
COS-NO).
Planktonic inhibition assays. Bacteria were grown as overnight cul-
tures, diluted 1:100 in fresh LB broth, grown to mid-log phase (2  108
CFU/ml), and diluted to 2  106 CFU/ml in LB broth. The bacterial
cultures were then added to vials containing 2-fold serial dilutions of
COS-NO or COS controls and incubated at 37°C for 18 h with gentle
shaking. The MIC was determined to be the minimum concentration that
prevented visible growth, defined as an optical density at 600 nm of 	0.1.
All untreated (control) cultures became visibly turbid during the 18-h
growth period. The corresponding NO dose was calculated by multiplying
the MIC of COS-NO (in milligrams per milliliter) with the available NO
in aerobic and anaerobic broth (in micromoles NO per milligram COS-
NO). Nitrate-supplemented LB was used for all stages of bacterial growth
and exposure. Anaerobic experiments were performed in a Coy anaerobic
chamber.
Biofilm eradication assays. Bacteria were grown as overnight cul-
tures, diluted 1:100 in fresh LB broth, and grown to mid-log phase (2 
108 CFU/ml). The bacterial cultures were then diluted to 106 CFU/ml in
diluted (25%) LB broth supplemented with 15 mM KNO3 (pH 6.5) and
grown for 72 h at 37°C with gentle shaking. The viscous microcolony
biofilms formed were easily separated from the growth media via pi-
petting. The biofilms were harvested by placing a pipette tip near the
center of the biofilm and applying suction. The biofilms were then washed
by injection into PBS and extracted using the same pipetting procedure to
remove planktonic or loosely associated bacteria. The freshly washed bio-
films (250 l) were combined with 750 l of PBS (pH 6.5); added to vials
containing COS, COS-NO, or tobramycin; and incubated with gentle
shaking for 18 h at 37°C. After treatment, the biofilms were washed via
pipetting in PBS to remove excess antibacterial agent, transferred to 750
l of PBS (pH 6.5), and gently sonicated to disrupt the biofilm matrix. The
dispersed biofilms were vortexed, serially diluted, plated, and enumerated
on LB agar. The minimum biofilm eradication concentration at 18 h
(MBEC
18 h
) was defined as the concentration that caused a 5-log-unit
reduction in viable bacteria (i.e., 108 to 103 CFU/ml) after the 18-h
treatment. The corresponding NO dose was calculated by multiplying
the MBEC18 h of COS-NO (in milligrams per milliliter) with the avail-
able NO in aerobic and anaerobic PBS (in micromoles NO per milli-
gram COS-NO).
Statistical analysis. All data are expressed as the mean 
 1 standard
deviation and were analyzed for significance (P 	 0.05) with a two-tailed
Student t test.
RESULTS
Nitric oxide release from COS-NO in media. Nitric oxide release
from COS-NO was measured via chemiluminescence in deoxy-
genated PBS (pH 6.5) at 37°C to yield total NO release payloads of
0.86 
 0.05 mol NO/mg, with an overall release duration of
10.2 
 2.7 h (see Fig. S1 in the supplemental material). While NO
release from macromolecular scaffolds is generally measured in
deoxygenated medium, measuring the amount of bioavailable
(i.e., nonscavenged) NO is critical for elucidating the biocidal
dose-response relationship of NO under the intended conditions,
as NO is rapidly scavenged by oxygen and proteins in biological
media (45). Unfortunately, foaming associated with nutrient-rich
medium makes chemiluminescence detection difficult and irre-
producible (43). Thus, we turned to amperometric NO detection
to carry out NO measurements in broth (LB).
In the absence of NO scavenging (i.e., in deoxygenated PBS),
amperometric measurements revealed a total NO payload of
0.34 
 0.17 mol/ml from the 1.0-mg/ml solution of COS-NO
over 4 h (Fig. 1). As might be expected, both the total NO payload
and the release duration of COS-NO measured via amperometry
were reduced compared to chemiluminescence detection. These
decreases are common for electrochemical sensors that are based
on the diffusion of NO to the working electrode and the inherent
loss of NO to the ambient atmosphere (43).
Under aerobic conditions, oxygen scavenging reduced the
amount of free NO available in PBS by approximately 35%
(0.22 
 0.08 mol NO/ml). Nutrient broth (LB) further dimin-
ished the available NO payload via scavenging of the NO by pro-
teins in the broth. The amount of NO available in anaerobic LB
broth was reduced to 0.14 
 0.08 mol NO/ml, a 66% reduction
relative to anaerobic PBS. Further reductions (0.027 
 0.017
mol/ml) were observed in aerobic LB broth due to reaction of
NO with oxygen.
Bactericidal action of the COS scaffold. To confirm that NO
and not the scaffold was responsible for the observed bacterial
killing, all bacterial assays were performed using NO-releasing
and control (i.e., non-NO-releasing) chitosan oligosaccharides. In
MBC4 h assays of planktonic cells, COS did not influence bacterial
viability at 1 or 10 the MBC4 h of COS-NO, indicating that the
FIG 1 Electrochemical measurements of available NO in media. (A) Representative NO release profiles for 1.0 mg/ml of COS-NO in anaerobic PBS,
aerobic PBS, anaerobic LB broth, and aerobic LB broth. (B) The values from panel A were integrated to find the total concentrations of available NO in
a 1.0-mg/ml solution of COS-NO in biological media after 4 h. The error bars indicate standard deviations.
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chitosan oligosaccharide alone was not bactericidal (see Fig. S2 in
the supplemental material). Similarly, bacterial viability was not
reduced upon treatment of the biofilms with 4.0 mg COS/ml (1
the MBEC18 h) for 18 h under both aerobic and anaerobic condi-
tions (see Fig. S3 in the supplemental material). Based on these
data, the bactericidal activity of COS-NO was attributed solely to
the effects of NO and not to toxicity of the COS scaffold.
Effect of oxygen on bactericidal action of NO against plank-
tonic P. aeruginosa. The biocidal action of NO was evaluated with
respect to the oxygen concentration in the treatment medium by
exposing planktonic cultures to COS-NO in both aerobic and an-
aerobic PBS (pH 6.5) (Table 1). When grown under aerobic con-
ditions, the same concentration of COS-NO (100 g/ml) was re-
quired to eradicate both the mucoid and nonmucoid strains.
Furthermore, oxygen in the exposure medium did not alter the
bactericidal concentration of COS-NO. However, the NO dose
delivered was slightly greater under anaerobic exposure condi-
tions due to the decreased reactions between NO and oxygen. For
example, the bactericidal NO dose was 0.022 
 0.008 mol
NO/ml under aerobic conditions versus 0.034 
 0.017 mol
NO/ml in deoxygenated (anaerobic) medium. This difference in
the NO payload was not statistically significant.
Bacterial cultures were also grown aerobically and anaerobi-
cally to determine if oxygen in the growth medium affected P.
aeruginosa susceptibility to NO. As anaerobic growth requires ni-
trate, all assays were carried out using nitrate-supplemented LB
medium to enable direct comparison. The absence of oxygen in
the growth medium had no effect on the susceptibility of nonmu-
coid P. aeruginosa to NO. However, strict anaerobic growth of
mucoid P. aeruginosa increased the tolerance of the strain for NO
by 2-fold (MBC4 h  0.044 
 0.016 and 0.022 
 0.008 mol
NO/ml for anaerobic and aerobic growth conditions, respectively)
(Table 1). The increased tolerance for NO was observed under
both aerobic and anaerobic exposure conditions.
Inhibition of planktonic P. aeruginosa growth by COS-NO.
MIC assays were performed to evaluate the efficacy of COS-NO
during bacterial growth under aerobic and anaerobic environ-
ments (Table 2). Under aerobic conditions, the nonmucoid phe-
notype was more tolerant of COS-NO than the mucoid strain,
with inhibitory doses of 800 g COS-NO/ml (0.022 
 0.014 mol
NO/ml) versus 400 g COS-NO/ml (0.011 
 0.007 mol NO/
ml), respectively. Anaerobic conditions decreased the MIC to 100
g COS-NO/ml (0.014 mol NO/ml) for both phenotypes. While
the COS-NO concentration required to inhibit growth was re-
duced in anaerobic environments, the NO dose delivered was not
significantly lower, indicating that NO lost to reaction with oxy-
gen accounts for the increased MICs against COS-NO under aer-
obic conditions.
Inhibition of growth by COS-NO for clinical isolates, includ-
ing tobramycin-resistant strains. To ensure that the increased
inhibition of bacterial growth by COS-NO under anaerobic con-
ditions was not solely a function of the laboratory P. aeruginosa
strain used, 10 clinical isolates of P. aeruginosa were tested, includ-
ing mucoid, nonmucoid, and tobramycin-resistant isolates. The
concentrations of COS-NO required to inhibit growth under an-
aerobic conditions were less than or equal to those under aerobic
conditions for all 10 isolates (Fig. 2A). There was no statistical
difference in the NO dose required to inhibit growth for most of
the strains tested (Fig. 2B). However, two isolates (Fig. 2B, aster-
isks) showed a statistically significant increase in the NO dose
required to inhibit growth under anaerobic conditions relative to
aerobic conditions. Overall, COS-NO was more effective at inhib-
iting growth under anaerobic environments, but the efficacy of
NO was unchanged for most of the isolates tested.
As with the laboratory strain, differences were seen between the
mucoid and nonmucoid phenotypes (Fig. 2). Mucoid strains were
more susceptible to COS-NO, as indicated by the low MIC range
(25 to 200 g COS-NO/ml) relative to nonmucoid strains (MIC
range, 100 to 400 g COS-NO/ml). No apparent differences were
observed between tobramycin-susceptible and tobramycin-resis-
tant strains of the same phenotype; however, more isolates would
be needed to confirm the statistical significance of these trends.
TABLE 1 Effects of oxygen on nongrowing planktonic culturesa
Strain Growth medium






(g COS-NO/ml) NO doseb (mol NO/ml)
Nonmucoid Aerobic 100 0.022 
 0.008 100 0.034 
 0.017
Anaerobic 100 0.022 
 0.008 100 0.034 
 0.017
Mucoid Aerobic 100 0.022 
 0.008 100 0.034 
 0.017
Anaerobic 200 0.044 
 0.016 200 0.068 
 0.033
a P. aeruginosa cultures were grown in LB broth (plus 15 mM KNO3) under aerobic or anaerobic conditions and then exposed to COS-NO in PBS (pH 6.5) for 4 h under aerobic or
anaerobic conditions.
b Determined via amperometry. The values are presented as means 
 standard deviations for 3 or more pooled experiments.
TABLE 2 Influence of oxygen on the inhibitory efficacy of COS-NOa
Growth medium
Nonmucoid strain Mucoid strain
MIC (g COS-NO/ml) NO doseb (mol NO/ml) MIC (g COS-NO/ml) NO doseb (mol NO/ml)
Aerobic 800 0.022 
 0.014 400 0.011 
 0.007
Anaerobic 100 0.014 
 0.008 100 0.014 
 0.008
a Bacterial cultures in mid-log-phase growth were diluted to 2  106 CFU/ml in LB broth (plus 15 mM KNO3) with COS-NO and grown for 18 h under aerobic or anaerobic
conditions. The MIC was determined as the concentration of COS-NO that visibly inhibited growth.
b Determined via amperometry. The values are presented as means 
 standard deviations for 3 or more pooled experiments.
Anaerobic Bactericidal Action of Nitric Oxide
October 2015 Volume 59 Number 10 aac.asm.org 6509Antimicrobial Agents and Chemotherapy
Biofilm eradication by COS-NO and tobramycin. As bacterial
biofilms exist in both aerobic and anaerobic environments (46), it
was important to determine how oxygen concentrations affected
the antibiofilm activity of COS-NO. Under aerobic conditions,
highly viscous microcolony biofilms were formed (250 l in
volume) with bacterial viability of 4.0 
 0.6  108 and 2.5 
 0.5 
108 CFU/ml for nonmucoid and mucoid phenotypes, respectively.
Of note, nitrate supplementation was required to prevent pheno-
typic switching from the mucoid to the nonmucoid phenotype
(47). Under anaerobic growth conditions, we were unable to cause
the bacteria to form robust biofilms even after 7 days of growth.
Bacterial biofilms were exposed to COS-NO for 18 h in PBS
(pH 6.5) under aerobic or anaerobic conditions. The MBEC18 h
values for the two phenotypes were 4,000 g COS-NO/ml and
1,000 g COS-NO/ml (0.88 
 0.33 and 0.34 
 0.17 mol NO/ml)
under aerobic and anaerobic conditions, respectively (Table 3).
These results indicate that NO released from a scaffold is equally
effective at eliminating biofilms derived from nonmucoid and
mucoid strains. Moreover, NO is significantly more effective at
eliminating biofilms in the absence of oxygen.
The MBEC18 h of tobramycin against biofilms was determined
under the same conditions (i.e., 18-h exposure in PBS) to allow
comparison of NO to current antibiotic therapies. Under aerobic
environments, the nonmucoid strain was eradicated at lower con-
centrations of tobramycin than the mucoid strain (200 and 800
g/ml, respectively) (Table 4). Both strains required greater to-
bramycin levels (1,600 g/ml) to eradicate bacterial biofilms un-
der anaerobic conditions.
DISCUSSION
We have previously reported on the antibacterial activity of NO
against planktonic and biofilm-based P. aeruginosa (14, 15, 39).
However, little is understood regarding how oxygen and the bac-
terial phenotype impact NO’s efficacy. Such knowledge is critical
in the development of NO-based therapeutics. Water-soluble
NO-releasing chitosan oligosaccharides were used as the NO re-
lease scaffold in the studies described here due their biocompati-
bility and ability to be degraded in vivo (40, 41, 48). Although
chitosan is a known bactericidal agent, the reduced molecular
mass (to ensure water solubility) and 2-methylaziridine modifica-
tion (for NO donor addition) resulted in a material with no bac-
tericidal activity (see Fig. S2 and S3 in the supplemental material).
It is well known that NO reacts with oxygen and superoxide to
form highly reactive intermediates that facilitate bacterial killing
through oxidative and nitrosative stresses (19, 49). As oxygen
plays an integral role in the antibacterial action of NO, anaerobic
environments may reduce the biocidal efficacy of NO (20, 50).
However, NO also reacts with oxygen to form nitrate and nitrite.
These seemingly paradoxical roles of oxygen in NO-mediated kill-
ing are not fully understood. Therefore, we carried out electro-
chemical measurements of NO under aerobic and anaerobic con-
ditions to quantify the amounts of bioavailable NO. Under
FIG 2 MICs against clinical isolates of P. aeruginosa. (A) Minimum concentrations of COS-NO resulting in no bacterial growth for nonmucoid, mucoid, and
tobramycin-resistant isolates. (B) Corresponding NO dose for each isolate under aerobic and anaerobic environments. All bacteria were grown and exposed in
LB medium supplemented with nitrate (pH 6.5) for 18 h. Statistically significant differences (P 	 0.05) between aerobic and anaerobic NO payloads are indicated
by the asterisks. The error bars indicate standard deviations.
TABLE 3 Bactericidal efficacy of COS-NO against P. aeruginosa biofilmsa
Strain
Aerobic exposure Anaerobic exposure
MBEC (g COS-NO/ml) NO doseb (mol NO/ml) MBEC (g COS-NO/ml) NO doseb (mol NO/ml)
Nonmucoid 4,000 0.88 
 0.33 1,000 0.34 
 0.17
Mucoid 4,000 0.88 
 0.33 1,000 0.34 
 0.17
a Biofilms were exposed to COS-NO in PBS (pH 6.5) for 18 h under aerobic or anaerobic conditions. The MBEC18 h is reported as the concentration of COS-NO required for 5-log-
unit reduction in biofilm viability.
b Determined via amperometry. The values are presented as means 
 standard deviations for 3 or more pooled experiments.
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aerobic conditions, the measured NO decreased by 35% com-
pared to anaerobic conditions (Fig. 1). To elucidate the effects of
oxygen availability in treatment media, bacteria were first grown
aerobically and then exposed to COS-NO in aerobic or anaerobic
PBS. Identical concentrations of COS-NO were required to kill P.
aeruginosa regardless of the treatment conditions. Due to the re-
action of NO with oxygen, the bioavailable concentration of NO
(i.e., the NO dose) was slightly, but not significantly, higher under
anaerobic conditions (Table 1). As such, oxygen availability in the
treatment medium has no statistically significant effect on the bio-
cidal activity of NO released from COS-NO.
While the oxygen concentration in the exposure medium did
not alter the bactericidal efficacy of NO, the presence of oxygen
during bacterial growth did influence P. aeruginosa susceptibility
to NO. Anaerobic growth conditions reduce the efficacy of current
antibiotics by altering certain properties of the bacteria, such as
alginate production (46) and metabolic rates (10). To separate
these factors, MBC4 h assays were performed under nonnutritive
conditions to minimize the effects of bacterial metabolism on the
bactericidal activity of NO. When bacteria were grown under an-
aerobic conditions, the efficacy of NO released from the chitosan
oligosaccharide scaffold was decreased against the mucoid, but
not the nonmucoid, phenotype, indicating that growing mucoid
bacteria without oxygen significantly alters their defense against
NO (Table 1). Worlitzsch et al. previously reported that P. aerugi-
nosa produces a protective alginate exopolysaccharide that is 50%
thicker when grown anaerobically (46). As alginate restricts the
diffusion of oxygen, the increased thickness of this protective layer
could potentially prevent NO diffusion into the bacteria, therefore
requiring a larger NO dose for killing.
To study the role of anaerobic growth on the efficacy of NO
and COS-NO, we evaluated the inhibition of P. aeruginosa growth
by COS-NO in nutrient-rich medium under both aerobic and
anaerobic conditions. In contrast to the static conditions of MBC4
h assays, bacteria are actively growing during inhibition assays.
Comparison of MIC values under oxygen and oxygen-free envi-
ronments showed that the efficacy of COS-NO was enhanced un-
der anaerobic conditions while there was no statistical difference
in the corresponding NO dose. This behavior was observed in the
laboratory strains (Table 2) and most of the clinical isolates tested
(Fig. 2). As the efficacy of NO is not reduced under anaerobic
environments, NO-based treatments represent a potential alter-
native to current antibiotic treatments, including aminoglyco-
sides and -lactams, which are less effective under anaerobic con-
ditions because their mechanism of action requires actively
dividing cells (51, 52).
It is important to characterize the antibiofilm activities of an-
tibacterial agents, as P. aeruginosa exists as biofilms on medical
implants (e.g., catheters) (53, 54), on burn wounds (55, 56), and in
the airways of patients with cystic fibrosis (57, 58). As shown in
Table 4, mucoid biofilms are significantly more resilient against
tobramycin than nonmucoid biofilms. Hentzer et al. attributed
decreased antibiotic efficacy against mucoid strains to the over-
production of alginate (59). As has been previously reported (60,
61), low-oxygen conditions further decrease the effectiveness of
tobramycin (the MBEC18 h is increased to 1,600 g/ml under an-
aerobic conditions). While tobramycin is a highly effective anti-
pseudomonal agent, these factors compromise its ability to kill P.
aeruginosa biofilms in oxygen-free environments. In contrast, NO
released from the chitosan scaffold was equally effective at eradi-
cating mucoid and nonmucoid biofilms. Similarly, the antibiofilm
activity was not reduced under anaerobic environments (Table 3).
Furthermore, the NO dose required for biofilm eradication under
anaerobic conditions is 0.34 
 0.17 mol NO/ml, 10-fold lower
than that of tobramycin (3.42 mol/ml) (Tables 3 and 4).
In conclusion, these studies examined the susceptibilities of
nonmucoid, mucoid, and biofilm P. aeruginosa phenotypes to
NO-releasing chitosan oligosaccharides as a function of oxygen
availability. The antibacterial activity of NO-releasing chitosan
oligosaccharides was enhanced in oxygen-free environments, de-
spite a concomitant decrease in the number of possible mecha-
nisms available to kill bacteria (i.e., fewer toxic by-products from
the reactions of NO and oxygen). Furthermore, the antibiofilm
action of NO was more effective than that of tobramycin and was
not influenced by the bacterial phenotype. When combined with
NO’s significant biocidal action against P. aeruginosa, these results
suggest that NO-releasing chitosan oligosaccharides may repre-
sent a potential alternative to traditional antibiotics, particularly
when treating biofilms or in low-oxygen environments. We are
currently seeking to enhance the NO payloads and evaluate the
effects of NO release kinetics on the antibacterial efficacy of chi-
tosan oligosaccharides.
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